Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Cogstate Ltd ( (AU:CGS) ).
Cogstate Ltd has applied to the ASX for quotation of 4,346 new ordinary fully paid shares, to be traded under its existing ticker CGS. The securities were issued on 24 March 2026 following the exercise or conversion of existing options or other convertible securities, representing a small increase in the company’s listed share capital with minimal expected impact on its overall capital structure or market positioning.
The application, lodged as a new announcement on 10 April 2026, confirms compliance with ASX Listing Rules governing the quotation of additional securities. While the volume is modest, the move formalizes the listing of previously granted equity instruments, slightly broadening Cogstate’s tradable float and reflecting ongoing use of equity-based incentives or financing within the company’s capital management strategy.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is an Australian-listed company on the ASX under the code CGS. The company operates in the healthcare and life sciences technology sector, providing cognitive assessment solutions and related services, with a focus on supporting clinical trials, research, and the evaluation of cognitive function in various therapeutic areas.
Average Trading Volume: 191,072
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$410.4M
See more data about CGS stock on TipRanks’ Stock Analysis page.